|
CLASSIF1 Classification
|
Pretherapeutic Identification of High Risk AML Patients
- Eight patient and clinical chemistry parameters, one overall
survival (OS) indicator for clinical outcome,
25 cytogenetic abnormalities and 36 flow cytometric
immunophenotype parameters at diagnosis were available for classification.
One color indirect (FITC-F(ab')2 fragments (
L2
)) immunophenotypes were used throughout the study for reasons
of compatibility with the early determinations of the multicenter
trial.
1965-2006:
Max-Planck-Institut für Biochemie, Am Klopferspitz 18a,
D-82152 Martinsried, Germany
Last update: Apr 14,2003
First display: Mar 31,2003